跳至主要内容
临床试验/ISRCTN06278310
ISRCTN06278310已完成3 期

ebivolol or Metoprolol in Arterial Occlusive Disease: A double-blind, randomised controlled trial

Berlin-Chemie (Germany) (part of Menarini Group [Italy])0 个研究点目标入组 128 人开始时间: 2010年6月24日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male patients 30 years to 80 years or female postmenopausal patients up to 80 years
  • 2. Arterial occlusive disease Fontaine´s stage II A or B
  • 3. Stage I hypertension according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) with or without hypertensive treatment

排除标准

  • 1. Arterial occlusive disease with rest pain or leg ulcer
  • 2. Any concomitant disease limiting the exercise capacity of the patient
  • 3. Poorly controlled diabetes HbA1c > 10%
  • 4. Acute myocardial infarction during the last 6 month
  • 5. Treatment with COX-2 inhibitors
  • 6. Previous treatment with nebivolol or carvedilol
  • 7. Concomitant treatment with drugs that may influence endothelial function
  • 8. Contraindication to the study drug
  • 9. Participation in an other clinical trail the last 6 month
  • 10. Acute pathologic haemorrhage
  • 11. Known hyperthyoidism
  • 12. Psychiatric diseases
  • 13. Known hypersensivity to nebivolol or metoprolol
  • 14. Prior or active malignancy in the previous 5 years
  • 15. History of drug or alcohol abuse
  • 16. Unwilling or unable to provide informed consent

研究者

发起方
Berlin-Chemie (Germany) (part of Menarini Group [Italy])

相似试验